Obesity Drug Data Sparks Buzz: Recent posts on X have been abuzz with Neumora Therapeutics’ latest preclinical results for NMRA-215, an oral NLRP3 inhibitor showing significant weight loss in studies. The data has driven a notable uptick in the stock price, with some users highlighting its potential to compete in the obesity treatment market. This excitement reflects a growing interest in the biotech sector’s innovation.
Clinical Trials Underway: Discussions on X also focus on Neumora’s initiation of a Phase 1 trial for NMRA-898, a muscarinic PAM, aimed at addressing brain-related treatments. Many users are keenly awaiting updates, expected by mid-2026, as a sign of the company’s pipeline strength. The tone around these developments remains optimistic as investors track progress.
Note: This discussion summary was generated from an AI condensation of post data.
Neumora Therapeutics Insider Trading Activity
Neumora Therapeutics insiders have traded $NMRA stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $NMRA stock by insiders over the last 6 months:
- KRISTINA BUROW purchased 1,915,700 shares for an estimated $4,999,977
- VENTURE PARTNERS X, LLC ARCH purchased 1,915,700 shares for an estimated $4,999,977
- VENTURE PARTNERS XII, LLC ARCH purchased 1,915,700 shares for an estimated $4,999,977
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Neumora Therapeutics Hedge Fund Activity
We have seen 49 institutional investors add shares of Neumora Therapeutics stock to their portfolio, and 72 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. removed 3,472,424 shares (-54.6%) from their portfolio in Q2 2025, for an estimated $2,546,328
- UBS GROUP AG removed 2,455,852 shares (-79.1%) from their portfolio in Q2 2025, for an estimated $1,800,876
- STATE STREET CORP removed 1,370,559 shares (-79.6%) from their portfolio in Q2 2025, for an estimated $1,005,030
- GEODE CAPITAL MANAGEMENT, LLC removed 1,059,487 shares (-53.6%) from their portfolio in Q2 2025, for an estimated $776,921
- TWO SIGMA ADVISERS, LP added 1,052,900 shares (+597.6%) to their portfolio in Q2 2025, for an estimated $772,091
- BANK OF AMERICA CORP /DE/ removed 797,642 shares (-91.8%) from their portfolio in Q2 2025, for an estimated $584,910
- GSA CAPITAL PARTNERS LLP added 717,030 shares (+384.0%) to their portfolio in Q2 2025, for an estimated $525,798
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Neumora Therapeutics Analyst Ratings
Wall Street analysts have issued reports on $NMRA in the last several months. We have seen 2 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- Needham issued a "Buy" rating on 10/28/2025
- Guggenheim issued a "Buy" rating on 10/27/2025
- JP Morgan issued a "Underweight" rating on 09/16/2025
To track analyst ratings and price targets for Neumora Therapeutics, check out Quiver Quantitative's $NMRA forecast page.
Neumora Therapeutics Price Targets
Multiple analysts have issued price targets for $NMRA recently. We have seen 3 analysts offer price targets for $NMRA in the last 6 months, with a median target of $8.0.
Here are some recent targets:
- Ami Fadia from Needham set a target price of $8.0 on 10/28/2025
- Yatin Suneja from Guggenheim set a target price of $14.0 on 10/27/2025
- Graig Suvannavejh from Mizuho set a target price of $5.0 on 07/16/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
